Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/Isis Lung Cancer NDA Possible In 2003; Lymphoma Indication In Phase II

Executive Summary

An NDA for the Isis drug 3521, licensed to Eli Lilly, could be submitted for non-small cell lung cancer by 2003.
Advertisement

Related Content

Lilly/Isis Affinitak Pivotal Trial Fails: Future Rests On Second Phase III Study
Lilly/Isis Affinitak Pivotal Trial Fails: Future Rests On Second Phase III Study
Lilly Affinitac Launch Supply Will Be Produced By Isis; Deliveries Start In 2003
Lilly Affinitac Launch Supply Will Be Produced By Isis; Deliveries Start In 2003
Aventis/Genta Genasense Lead Indication To Be Decided This Summer
Aventis/Genta Genasense Lead Indication To Be Decided This Summer
Advertisement
UsernamePublicRestriction

Register

PS038405

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel